14/08/2025
Anticipating a Price Increase for Mounjaro® in the UK
14 August 2025
From 1st September 2025, Eli Lilly & Company will be increasing the UK list price for Mounjaro® (tirzepatide) to bring it in line with prices across Europe and other developed countries.
While official list prices will be higher across all strengths, Lilly has confirmed that discounted prices will be offered to private providers. These will be lower than the list price, but still significantly above current levels, meaning patients paying privately should expect a noticeable increase.
This adjustment follows a review of current pricing, which found that the UK list price was significantly lower than the European average. At launch, Lilly intentionally set a lower price in the UK to ensure quick patient access during a period of global supply challenges for GLP-1 RA treatments. Now, with wider availability and growing clinical evidence supporting the treatment’s value, Lilly is realigning prices internationally.
What to Expect from the Change
Based on the new discounted retail prices, patients could see increases ranging from around 30% for some doses to well over 100% for others. Lower-dose options will see the smallest proportional rise, while some higher-dose strengths will more than double compared to current prices.
Lilly has stated that these changes are intended to:
Reduce the risk of UK supply being illegally exported for profit in higher-priced markets.
Ensure fair contributions toward the cost of ongoing research and development.
Support consistent access for patients worldwide.
NHS and Private Patient Access
For NHS patients, Lilly has reached an agreement to maintain cost-effectiveness as per NICE and SMC guidance, meaning that access should remain unaffected within the public system.
Private providers will receive commercial terms designed to help maintain patient access. However, the final cost to individuals will depend on provider pricing decisions, so patients paying out-of-pocket should expect higher costs from September.
A Pharmacist’s Perspective
"Patients should be aware that the scale of the upcoming price changes varies significantly depending on the Mounjaro dose they are prescribed. For some, the increase will be modest, but for others it could be substantial. My advice is to speak to your healthcare provider now, review your treatment plan, and explore whether there are options to ensure continued access without interruption."
Alessandro Grenci, Superintendent Pharmacist
What Patients Should Do Now
Check repeat prescriptions – If you are receiving Mounjaro privately, be aware that costs will rise from September.
Consult your healthcare provider – They can advise on treatment continuity, potential alternatives, or transitioning to NHS prescriptions if eligible.
Plan ahead financially – Patients paying out-of-pocket should prepare for higher monthly costs.
With the confirmed changes taking effect soon, both patients and healthcare providers are encouraged to plan ahead to avoid any interruptions to treatment.
